National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Seebri Breezhaler® is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).

Rapid Review

Commenced Completed Outcome
12 August 2012 17 August 2012 Full pharmacoeconomic evaluation not recommended